Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine in Stage D Heart Failure and Cardiogenic Shock
NCT03387605Phase 4Unknown
- Sponsor
- Loyola University Chicago
- Start
- Mar 2018
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure (HF), cardiogenic shock and sinus tachycardia (ST) comparing Ivabradine Arm with Placebo Arm (2 arms). Primary endpoint: Heart rate at 72 hours. Status: unknown.
02
Drugs
ivabradine
03
Conditions
heart failure (HF)cardiogenic shocksinus tachycardia (ST)
Beyond the preview
Go deeper on NCT03387605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387605.